UPPSALA, 14 May, 2012 -- Isconova AB, a leading international vaccine adjuvant company, announces first results from a successful phase I study using the Company’s proprietary vaccine adjuvant, Matrix MTM. This study forms part of the
clinical proof of concept for Matrix MTM and its utility in improving the clinical efficacy of seasonal influenza
vaccines in the elderly. Both the primary as well as secondary clinical endpoints were reached.
In this trial, a group of elderly subjects (aged 65-75) were administered either Vaxigrip® (seasonal influenza
split vaccine) adjuvanted with Matrix MTM or Vaxigrip® alone. The adjuvanted vaccine was well tolerated with
an excellent safety profile. An increased number of minor side-effects compared to the non-adjuvanted
comparator vaccine were observed, however these were mild and transient. No severe side-effects were
Both the adjuvanted and non-adjuvanted vaccines fulfilled all three EMA serological assessment criteria for
regulatory approval of seasonal influenza vaccines. Higher antibody responses were seen in the Matrix MTM
Interferon gamma producing CD4 cells were found at significantly higher levels in the Matrix M™ group on
days 28 and 90 and were still elevated on day 150. These cells are considered to be an important marker of a
potent immune response.
The study confirms the clinical superiority of the Matrix M™ adjuvanted vaccine, already demonstrated by
the use of Matrix MTM in the previously conducted pandemic influenza vaccine study in man (PanFluVac), by
Isconova’s partner J&J / Crucell, including the important increase in the cell mediated immune response.
Professor Ab Osterhaus, world leading influenza expert and Chief Scientific Officer of ViroClinics Biosciences
BV, Rotterdam, commented;
“The adjuvant Matrix MTM performed remarkably well in this human trial. It stimulated both antibody and
cellular responses with an excellent safety profile.”
Sven Andréasson, Chief Executive Officer of Isconova AB, Uppsala, commented;
“This is an important achievement for us and is further evidence that Isconova’s proprietary Matrix M™
platform has the potential to improve vaccines for humans in a growing market where there remain major
unmet needs. The data are crucial for the proof of concept for our further commercialization of Matrix M™.”
For more information, please contact:
Sven Andréasson, Chief Executive Officer of Isconova AB
Tel: +46 701 60 60 60
Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden.
Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO). Pareto Öhman AB is the Company’s Certified Adviser.
About the influenza study
- Vaxigrip® (seasonal influenza split vaccine) adjuvanted with Matrix MTM was tested and
compared with Vaxigrip® alone in two groups (n= 44 per group) of elderly subjects , aged 65-
- The specific T-cell mediated response was significantly higher in the group receiving the
Matrix MTM adjuvanted vaccine. This was measured with respect to the percentage of
influenza virus reactive CD4+ cells producing:
- Interferon gamma at day 28 and 90 (P<0.05).
- Both the adjuvanted and non-adjuvanted vaccines induced high levels of antibodies and both
groups conform to all three EMA serological assessment criteria for regulatory approval of
seasonal influenza vaccines;
- The Hemagglutination Inhibition (HI) Seroconversion Rate;
was higher against all three strains in the Matrix MTM adjuvanted vaccine. Even at day
150, seroconversion rates were 8% or higher among elderly receiving the Matrix MTM
- The Geometric Mean Titer (GMT) increase of HI;
was higher for all three strains in the Matrix MTM adjuvanted vaccine at day 28 and
- The Seroprotection Rate by HI;
was equal or higher for all three strains in the Matrix MTM adjuvanted vaccine at day 28
- The GMT increase of Virus Neutralization Antibodies (VNA) was significantly higher for the
homologous H1N1 strain in the Matrix MTM adjuvanted vaccine group at day 28 and 90. In
addition, the GMT increase of VNA was higher for the homologous B strain in the Matrix MTM
adjuvanted vaccine group at day 28 and 150.
- The Matrix MTM adjuvanted vaccine was well tolerated. An expected increase of minor side-
effects compared to the non-adjuvanted comparator vaccine was observed. The reactogenicity
was mild and transient. No severe side effects were recorded.
- The results of this phase I study in elderly subjects demonstrate that Matrix MTM is well
tolerated and significantly stimulates the T-cell response. Furthermore, the results indicate an
increase of the serological response and duration.
- The study forms a part of the clinical proof of concept for the further development of
Matrix MTM adjuvanted seasonal influenza vaccines with the potential for an increased clinical
efficacy in the elderly population.